Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000, C546S113000, C546S115000, C546S117000, C546S118000, C546S120000, C514S300000, C514S302000, C514S303000
Reexamination Certificate
active
10542214
ABSTRACT:
The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
REFERENCES:
patent: 4386090 (1983-05-01), Moinet et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6166063 (2000-12-01), Villhauer
patent: 6265418 (2001-07-01), Kuroki et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6432969 (2002-08-01), Villhauer
patent: 6699871 (2004-03-01), Edmondson et al.
patent: 7157490 (2007-01-01), Colandrea et al.
patent: WO97/40832 (1997-11-01), None
patent: WO98/19998 (1998-05-01), None
patent: WO98/19998 (1998-05-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/42262 (2001-06-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/076450 (2002-10-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 2005/002530 (2003-01-01), None
patent: WO 03/082817 (2003-10-01), None
patent: WO 2004/007468 (2004-01-01), None
patent: WO 2004/007468 (2004-01-01), None
patent: WO 2004/032836 (2004-04-01), None
patent: WO 2004/043940 (2004-05-01), None
patent: WO 2004/050022 (2004-06-01), None
patent: WO 2004/058266 (2004-07-01), None
patent: WO 2004/064778 (2004-08-01), None
patent: WO 2004/069162 (2004-08-01), None
patent: WO 2004/110436 (2004-12-01), None
patent: WO 2004/112701 (2004-12-01), None
patent: WO 2004/112701 (2004-12-01), None
patent: WO 2005/011581 (2005-02-01), None
patent: WO 2005/044195 (2005-05-01), None
patent: WO 2005/056003 (2005-06-01), None
patent: WO 2005/056013 (2005-06-01), None
J. J. Holst, “Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors”, Expert Opin. Emerg. Drugs, vol. 9(1) pp. 155-166, 2004.
C. F. Deacon, et al., “Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?”, Expert Opin. Investig. Drugs, vol. 13(9) pp. 1091-1102, 2004.
K. Augustyns et al., “Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes”, Expert Opin. Ther. Patents, vol. 13(4), pp. 499-510, 2003.
Novartis AG: WO0034241, “Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus”, Exp. Opin. Ther. Patents, vol. 10(12), pp. 1937-1942, 2000.
O. J. Orucker, “Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes”, Exp. Opin Invest. Drugs, vol. 12, 2004, pp. 87-100.
T. P. Vahl & D. A. D'Alessio, “Gut peptides in the treatment of diabetes mellitus” Exp. Opin. Invest. Drugs, vol. 13, 2004, pp. 177-188.
L. B. Knudsen, “Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes”, J. Med. Chem, vol. 47, 2004, pp. 4128-4134.
Ann E. Weber, “Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes”, J. Med. Chem, vol. 47, 2004, pp. 4135-4141.
J. J. Holst and C. F. Deacon, “Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus”, Curr. Opin Pharmacology, vol. 4, 2004, pp. 589-596.
C. F. Deacon, “Perspectives in Diabetes—Therapeutic Strategies Based on Glucagon-Like Peptide 1”, Diabetes, vol. 53, Sep. 2004, pp. 2181-2189.
Kuroki, et al, DAtabase CAPLUS on STN No. 130:1685654, 1999.
Burger, A Guide to the Chemical Basis of Drug Design, p. 15 (1983).
Ashton Wallace T.
Caldwell Charles G.
Mathvink Robert J.
Ok Hyun O.
Reigle Leah Bitalac
Aulakh Charanjit S.
Durette Philippe L.
Fitch Catherine D.
Merck & Co. , Inc.
LandOfFree
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793946